Stock Track | Halozyme Therapeutics Soars 5.39% in After-Hours Trading on Q2 Earnings Beat and Raised Guidance

Stock Track08-07

Halozyme Therapeutics (HALO) stock soared 5.39% in after-hours trading on Thursday, driven by investor enthusiasm following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.

The company reported adjusted earnings per share of $2.28, easily beating the consensus estimate of $1.84, while revenue surged 48% year-over-year to $481 million, ahead of the $407.5 million forecast. The strong performance was fueled by a 50% jump in royalty revenue from key partner products, including VYVGART Hytrulo and DARZALEX SC, as well as higher product sales. Additionally, Halozyme raised its full-year 2026 guidance, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS of $8.65 to $9.00, up from its prior outlook. The company also repurchased $332.8 million in shares during the quarter, further signaling confidence in its growth trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160744891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 09:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160744891","market":"sg","top_or_hot":-1,"title":"Stock Track | Halozyme Therapeutics Soars 5.39% in After-Hours Trading on Q2 Earnings Beat and Raised Guidance","media":"Stock Track","content":"<p>Halozyme Therapeutics (HALO) stock soared 5.39% in after-hours trading on Thursday, driven by investor enthusiasm following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.</p><p>The company reported adjusted earnings per share of $2.28, easily beating the consensus estimate of $1.84, while revenue surged 48% year-over-year to $481 million, ahead of the $407.5 million forecast. The strong performance was fueled by a 50% jump in royalty revenue from key partner products, including VYVGART Hytrulo and DARZALEX SC, as well as higher product sales. Additionally, Halozyme raised its full-year 2026 guidance, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS of $8.65 to $9.00, up from its prior outlook. The company also repurchased $332.8 million in shares during the quarter, further signaling confidence in its growth trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Halozyme Therapeutics Soars 5.39% in After-Hours Trading on Q2 Earnings Beat and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Halozyme Therapeutics Soars 5.39% in After-Hours Trading on Q2 Earnings Beat and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-07 09:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Halozyme Therapeutics (HALO) stock soared 5.39% in after-hours trading on Thursday, driven by investor enthusiasm following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.</p><p>The company reported adjusted earnings per share of $2.28, easily beating the consensus estimate of $1.84, while revenue surged 48% year-over-year to $481 million, ahead of the $407.5 million forecast. The strong performance was fueled by a 50% jump in royalty revenue from key partner products, including VYVGART Hytrulo and DARZALEX SC, as well as higher product sales. Additionally, Halozyme raised its full-year 2026 guidance, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS of $8.65 to $9.00, up from its prior outlook. The company also repurchased $332.8 million in shares during the quarter, further signaling confidence in its growth trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1160744891","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160744891","pubTimestamp":1786065992,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Halozyme Therapeutics (HALO) stock soared 5.39% in after-hours trading on Thursday, driven by investor enthusiasm following the release of its second-quarter financial results, which significantly...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"股票跟踪 | Halozyme Therapeutics 第二季度盈利超出预期并上调指引，盘后交易中股价飙升 5.39%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"Halozyme Therapeutics (HALO) stock soared 5.39% in after-hours trading on Thursday, driven by investor enthusiasm following the release of its second-quarter financial results, which significantly exceeded Wall Street expectations.The company reported adjusted earnings per share of $2.28, easily beating the consensus estimate of $1.84, while revenue surged 48% year-over-year to $481 million, ahead of the $407.5 million forecast. The strong performance was fueled by a 50% jump in royalty revenue from key partner products, including VYVGART Hytrulo and DARZALEX SC, as well as higher product sales. Additionally, Halozyme raised its full-year 2026 guidance, now projecting total revenue between $1.835 billion and $1.910 billion and non-GAAP diluted EPS of $8.65 to $9.00, up from its prior outlook. The company also repurchased $332.8 million in shares during the quarter, further signaling confidence in its growth trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160744891","isCrawlerRequest":true}